XenoPort, Reckitt Benckiser in licensing deal for alcoholism treatment

|About: XenoPort, Inc. (XNPT)|By:, SA News Editor

XenoPort (XNPT) has signed a licensing deal for Reckitt Benckiser (RBGLY) to develop XenoPort's Arbaclofen Placarbil treatment for alcoholism.

XenoPort will receive $20M upfront, $5M after certain technology and materials have been transferred, up to $70M in development and regulatory milestones, and $50M for commercial achievements.

Reckitt Benckiser will also start Phase IIb trials of Arbaclofen Placarbil. (PR)